Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urinary Bladder, Overactive Clear all
Not listed No phase listed Observational

Treatment of Overactive Bladder With a Digital Conversational Agent: the MOTIVATION Study

NCT04853849
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Pelvic Floor Disorders
Interventions
Not listed
Lead sponsor
Renalis
Industry
Eligibility
40 Years and older · Female only
Enrollment
50 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Urodynamic Testing: Can we Improve Patient Experience?

NCT02742389
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Overactive, Lower Urinary Tract Symptoms
Interventions
Preprocedure Telephone Call
Other
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Phase 2 Interventional

MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.

NCT00174798
View directory record Official record
Conditions
Overactive Bladder
Interventions
SSR240600C, Placebo, Tolterodine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Phoenix, Arizona • Tuscon, Arizona • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 23, 2026, 5:12 AM EDT
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02757768
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Mirabegron, Placebo, Tamsulosin Hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

NCT00454740
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
solifenacin succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
104
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 23, 2026, 5:12 AM EDT
Recruiting Early Phase 1 Interventional

Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms

NCT07648290
View directory record Official record
Conditions
Overactive Bladder
Interventions
Macrobid® Capsules 100 mg, Standard Medical Care (SMC)
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease

NCT01421719
View directory record Official record
Conditions
Parkinson's Disease, Neurogenic Bladder, Urinary Incontinence, Clostridium Botulinum Toxin Adverse Reaction
Interventions
Cystoscopic injection of Botox into the urinary bladder
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 23, 2026, 5:12 AM EDT
Terminated Phase 3 Interventional Results available

Over Active Bladder Instillation Study - Botox

NCT00667095
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Urge Incontinence
Interventions
Botox Instillation, DMSO Instillation
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 23, 2026, 5:12 AM EDT
Not yet recruiting Phase 4 Interventional

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

NCT07187466
View directory record Official record
Conditions
Overactive Bladder, Parkinson Disease
Interventions
mirabegron, Exercise-based behavioral therapy
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Decatur, Georgia • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

NCT00902187
View directory record Official record
Conditions
Treatment of Overactive Bladder
Interventions
Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

NCT00911937
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
112
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 23, 2026, 5:12 AM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Not applicable Interventional Results available

Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

NCT06059066
View directory record Official record
Conditions
Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
Interventions
Standard number of injection sites, Reduced number of injection sites
Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transvaginal Radiofrequency Ablation for Overactive Bladder

NCT06458556
View directory record Official record
Conditions
Overactive Bladder
Interventions
Treatment with Morpheus
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Corona del Mar, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Not applicable Interventional

FemPulse Therapy First-in-Human Experience

NCT03874637
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Treament, Sham Control
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Woodbury, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Phase 4 Interventional

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

NCT00224146
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence, Quality of Life
Interventions
oxybutynin transdermal delivery system (Oxytrol(r))
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Mobile, Alabama • Tucson, Arizona • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Sep 23, 2026, 5:12 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

NCT06034288
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Xeomin 100 UNT Injection, Botox 100 UNT Injection
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 23, 2026, 5:12 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA

NCT05519072
View directory record Official record
Conditions
Antibiotic Prophylaxis
Interventions
Nitrofurantoin
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 23, 2026, 5:12 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Bladder Botox UTI Antibiotic Prophylaxis

NCT06387329
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome
Interventions
Nitrofurantoin 100 MG
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need

NCT03136601
View directory record Official record
Conditions
Overactive Bladder
Interventions
PTNS maintenance
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 23, 2026, 5:12 AM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Sep 23, 2026, 5:12 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

NCT05221021
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Vaginal estrogen, Mirabegron 50 MG [Myrbetriq]
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 23, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

NCT01089751
View directory record Official record
Conditions
Overactive Bladder
Interventions
trospium chloride, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 23, 2026, 5:12 AM EDT